The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms

被引：7
|
作者：
Bartalucci, Niccolo
Bogani, Costanza
Martinelli, Serena
Mannarelli, Garmela
Villeval, Jean-Luc
Vannucchi, Alessandro M.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1599.1599
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1599
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Oncolytic HSV and PI3K inhibitor BKM120 synergize to promote killing of prostate cancer stem-like cells.
    Wang, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] Utilizing insulin the treatment of prostate cancer with BKM120 abrogates the therapeutic effect of PI3K pathway inhibition
    Wang, Lily C.
    Kim, Sunnie S.
    Nanus, David M.
    Cantley, Lewis C.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [23] Targeting the PI3K pathway in myeloproliferative neoplasms
    Gerds, Aaron T.
    Bartalucci, Niccolo
    Assad, Albert
    Yacoub, Abdulraheem
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 835 - 843
  • [24] ER Downregulation with Fulvestrant in Combination with pan-PI3K Inhibitor BKM120 Synergizes Against ER+/PI3K-Mutant Breast Cancer Xenografts In Vivo.
    Miller, T. W.
    Fox, E. M.
    Balko, J. M.
    Meszoely, I. M.
    Sanders, M. E.
    Kuba, M. G.
    Wagle, N.
    Garraway, L. A.
    Maira, S-M
    Arteaga, C. L.
    CANCER RESEARCH, 2011, 71
  • [25] UTILIZING INSULIN IN THE TREATMENT OF PROSTATE CANCER WITH BKM120 ABROGATES THE THERAPEUTIC EFFECT OF PI3K PATHWAY INHIBITION
    Wang, Lily
    Nanus, David
    Cantley, Lewis
    JOURNAL OF UROLOGY, 2015, 193 (04): : E547 - E547
  • [26] Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120
    Bashash, Davood
    Delshad, Mahda
    Safaroghli-Azar, Ava
    Safa, Majid
    Momeny, Majid
    Ghaffari, Seyed H.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2017, 91 : 1 - 8
  • [27] Phase II study of the PI3K inhibitor BKM120 monotherapy in patients with advanced or recurrent endometrial carcinoma: ENDOPIK, GINECO Study.
    Heudel, Pierre-Etienne
    Fabbro, Michel
    Roemer-Becuwe, Celia
    Treilleux, Isabelle
    Kaminsky, Marie-Christine
    Arnaud, Antoine
    Joly, Florence
    Forestier, Sophie Roche
    Herve, Robert
    Ray-Coquard, Isabelle
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors
    McRee, Autumn J.
    Sanoff, Hanna K.
    Carlson, Cheryl
    Ivanova, Anastasia
    O'Neil, Bert H.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (06) : 1225 - 1231
  • [29] Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells
    Wang, Lei
    Ning, Jianfang
    Wakimoto, Hiroaki
    Wu, Shulin
    Wu, Chin-lee
    Humphrey, Melissa R.
    Rabkin, Samuel D.
    Martuza, Robert L.
    MOLECULAR THERAPY-ONCOLYTICS, 2019, 13 : 58 - 66
  • [30] A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors
    Autumn J. McRee
    Hanna K. Sanoff
    Cheryl Carlson
    Anastasia Ivanova
    Bert H. O’Neil
    Investigational New Drugs, 2015, 33 : 1225 - 1231
12345